Sangamo Therapeutics, Inc. (SGMO)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sangamo Therapeutics, Inc. (“Sangamo” or “the Company”) (NASDAQ: SGMO). Investors who purchased Sangamo securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Sangamo has violated federal securities laws.
Investigation Details
During post-market hours on December 30, 2024, Sangamo announced that Pfizer would be returning the development and commercialization rights to hemophilia A gene therapy candidate giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. In a press release announcing this development, Sangamo stated that it was “surprised and extremely disappointed by Pfizer’s decision” to end the collaboration so close to anticipated Biologics License Application and Marketing Authorisation Application submissions for giroctocogene fitelparvovec, which the Company had expected to occur in early 2025. The collaboration and license agreement with Pfizer will terminate effective April 21, 2025, at which time Pfizer will be required to transition the giroctocogene fitelparvovec program back to Sangamo. On this news, Sangamo’s stock price fell sharply during intraday trading on December 31, 2024.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Sangamo securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]